Latest Breaking News On - Matt pera - Page 5 : comparemela.com

Inozyme Pharma, Inc Announces Proposed Offering of Common

BOSTON, July 27, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel.

United statesNew yorkMatt peraStefan rileyInozyme pharmaPiper sandlerCorporate communicationsProspectus departmentExchange commissionInozyme pharma incBofa securitiesTryon streetPrivate securities litigation reform actNasdaq inzyNozyme pharma inc

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDouglasa trecoInozyme pharmastefan rileyInozyme pharmaMatt peraExchange commissionEuropean medicines agencyDeficiency programInozyme pharma incDrug administrationPaediatric committeeCorporate communicationsPlanned pivotal trialPediatric patientsPrimary endpointsRadiographic global impression

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of

- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients -

United statesDouglasa trecoMatt peraInozyme pharmaStefan rileyExchange commissionDrug administrationCorporate communicationsEuropean medicines agencyInozyme pharma incPaediatric committeePlanned pivotal trialPediatric patientsPrimary endpointsRadiographic global impressionInvestor relations

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesStefan rileyInozyme pharmaMatt peraCorporate communicationsInozyme pharma incExchange commissionPrivate securities litigation reform actAnnual report

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation,

United statesKurt gunterMatt peraDavidr weberInozyme pharmaStefan rileyBone healthCorporate communicationsDivision of endocrinologyDeficiency program updatesInozyme pharma incExchange commissionMedical directorPrivate securities litigation reform actAnnual report